{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-082174","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.669139+00:00","generated_at":"2026-06-17T13:15:33.782925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Taysha reports Q4 net loss $55.7M; cash $87.9M; progress on Rett and GAN trials","bullets":["Net loss Q4 2022: $55.7M ($0.99/shr) vs $50.4M Q4 2021; full year loss $166.0M vs $174.5M.","Cash $87.9M at 12/31/22; expected to fund operations into Q1 2024.","TSHA-102: screening started for REVEAL trial; first adult dosing H1 2023; initial safety data expected H1 2023.","TSHA-120: FDA suggests alternative trial designs; formal meeting request planned Q2 2023.","Non-cash impairment charge of $36.4M in Q4 2022 for NC manufacturing facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-082174","json":"https://secwatch.observer/filing/0001193125-23-082174.json","markdown":"https://secwatch.observer/filing/0001193125-23-082174.md","text":"https://secwatch.observer/filing/0001193125-23-082174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/0001193125-23-082174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/d486592d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:15:33.782925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3184cc73aa0eaf76926382c058372191f37a685e","claim":"Taysha Gene Therapies, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2022.","evidence_excerpt":"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/0001193125-23-082174-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}